Selective small molecule angiotensin II type 2 receptor antagonists for neuropathic pain: Preclinical and clinical studies

Pain

Volumn 157, Issue , 2016, Pages S33-S41

  Smith, Maree T ^a   Anand, Praveen ^b   Rice, Andrew S C ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Angiotensin II; Angiotensin II type 2 receptor; AT2receptor knockout mice; Clinical mechanism of action; Clinical trial; Dorsal root ganglia; EMA200; EMA300; EMA401; Human DRG neurons; Peripheral neuropathic pain; Postherpetic neuralgia; Rodent neuropathic pain models; Small molecule AT2receptor antagonist; Target validation

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1 (4 METHOXY 3 METHYLBENZYL) 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANALGESIC AGENT; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; EMA 401; PD 126055; PLACEBO; RADIOLIGAND; UNCLASSIFIED DRUG;

ANALGESIA; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; BONE PAIN; CHRONIC CONSTRICTION INJURY; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DORSAL ROOT; DRUG BINDING; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; IMMUNOHISTOLOGY; INFLAMMATORY PAIN; LIGAND BINDING; NERVE CELL CULTURE; NEUROPATHIC PAIN; NEUROPATHY; NONHUMAN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PROSTATE CANCER; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SCIATIC NERVE; SENSORY NERVE CELL; SOMATOSENSORY SYSTEM; VALIDATION STUDY; ANIMAL; DOUBLE BLIND PROCEDURE; NEURALGIA; PRECLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANIMALS; DOUBLE-BLIND METHOD; DRUG EVALUATION, PRECLINICAL; HUMANS; NEURALGIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84961324803     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1097/j.pain.0000000000000369     Document Type: Conference Paper

References (44)

1. Anand U, Facer P, Yiangou Y, Sinisi M, Fox M, McCarthy T, Bountra C, Korchev YE, Anand P. Angiotensin II type 2 receptor (AT2R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons. Eur J Pain 2013;17:1012-26.
2. Anand U, Yiangou Y, Sinisi M, FoxM,MacQuillan A, Quick T, Korchev YE, Bountra C, McCarthy T, Anand P. Mechanisms underlying clinical efficacy of angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. Mol Pain 2015;11:39.
3. Backonja MM, Attal N, Baron R, Bouhassira D, Drangholt M, Dyck PJ, Edwards RR, Freeman R,Gracely R, HaanpaaMH, Hansson P, Hatem SM, Krumova EK, Jensen TS, Maier C, Mick G, Rice AS, Rolke R, Treede RD, Serra J, Toelle T, Tugnoli V, Walk D, Walalce MS, Ware M, Yarnitsky D, Ziegler D. Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. PAIN 2013;154:1807-19.
4. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell 2009;139:267-84.
5. Bhave G, Zhu W, Wang H, Brasier DJ, Oxford GS, Gereau RWIV. cAMPdependent protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct phosphorylation. Neuron 2002;35:721-31.
6. Black JA, Nikolajsen L, Kroner K, Jensen TS, Waxman SG. Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Ann Neurol 2008;64:644-53.
7. Chakrabarty A, Blacklock A, Svojanovsky S, Smith PG. Estrogen elicits dorsal root ganglion axon sprouting via a renin-angiotensin system. Endocrinology 2008;149:3452-60.
8. Chakrabarty A, Liao Z, Smith PG. Angiotensin II receptor type 2 activation is required for cutaneous sensory hyperinnervation and hypersensitivity in a rat hind paw model of inflammatory pain. J Pain 2013;14:1052-65.
9. Cote F, Do TH, Laflamme L, Gallo JM, Gallo-Payet N. Activation of the AT(2) receptor of angiotensin II induces neurite outgrowth and cell migration inmicroexplant cultures of the cerebellum. J Biol Chem 1999; 274:31686-92.
10. Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, Jensen TS, Sindrup SH. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, doubleblind, placebo-controlled phenotype-stratified study. PAIN 2014;155: 2263-73.
11. Dworkin RH, Turk DC, Peirce-Sandner S, Burke LB, Farrar JT, Gilron I, Jensen MP, Katz NP, Raja SN, Rappaport BA, Rowbotham MC, Backonja MM, Baron R, Bellamy N, Bhagwagar Z, Costello A, Cowan P, Fang WC, Hertz S, Jay GW, Junor R, Kerns RD, Kerwin R, Kopecky EA, Lissin D, Malamut R, Markman JD, McDermott MP, Munera C, Porter L, Rauschkolb C, Rice AS, SampaioC, Skljarevski V, Sommerville K, StaceyBR, Steigerwald I, Tobias J, Trentacosti AM, Wasan AD, Wells GA, Williams J, Witter J, Ziegler D. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. PAIN 2012;153:1148-58.
12. Dworkin RH, Turk DC, Peirce-Sandner S, McDermott MP, Farrar JT, Hertz S, Katz NP, Raja SN, Rappaport BA. Placebo and treatment group responses in postherpetic neuralgia vs. painful diabetic peripheral neuropathy clinical trials in the REPORT database. PAIN 2010;150: 12-16.
13. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I,HaanpaaM, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbothan M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14: 162-73.
14. Freeman R, Baron R, Bouhassira D, Cabrera J, Emir B. Sensory profiles of patients with neuropathic pain based on the neuropathic pain symptoms and signs. PAIN 2014;155:367-76.
15. Gendron L, Laflamme L, Rivard N, Asselin C, Payet MD, Gallo-Payet N. Signals from the AT2 (angiotensin type 2) receptor of angiotensin II inhibit p21ras and activate MAPK (mitogen-activated protein kinase) to induce morphological neuronal differentiation in NG108-15 cells. Mol Endocrinol 1999;13:1615-26.
16. Guimond MO, Roberge C, Gallo-Payet N. Fyn is involved in angiotensin II type 2 receptor-induced neurite outgrowth, but not in p42/p44mapk in NG108-15 cells. Mol Cell Neurosci 2010;45:201-12.
17. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol 2014;32:40-51.
18. Herichova I, Szantoova K. Renin-angiotensin system: upgrade of recent knowledge and perspectives. Endocr Regul 2013;47:39-52.
19. Imboden H, Patil J, Nussberger J, Nicoud F, Hess B, Ahmed N, Schaffner T, Wellner M, Muller D, Inagami T, Senbonmatsu T, Pavel J, Saavedra JM. Endogenous angiotensinergic system in neurons of rat and human trigeminal ganglia. Regul Pept 2009;154:23-31.
20. Jensen TS, Baron R, HaanpaaM, Kalso E, Loeser JD, Rice AS, Treede RD. A new definition of neuropathic pain. PAIN 2011;152:2204-5.
21. Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia. N Engl J Med 2014;371:1526-33.
22. Johnston CI. Franz Volhard Lecture. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens Suppl 1992;10:S13-26.
23. Kang J, Sumners C, Posner P. Modulation of net outward current in cultured neurons by angiotensin II: involvement of AT1 and AT2 receptors. Brain Res 1992;580:317-24.
24. Laflamme L, GasparoM,Gallo JM, PayetMD,Gallo-PayetN. Angiotensin II induction of neurite outgrowth by AT2 receptors in NG108-15 cells. Effect counteracted by the AT1 receptors. J Biol Chem 1996;271:22729-35.
25. Lucius R, Gallinat S, Rosenstiel P, Herdegen T, Sievers J, Unger T. The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med 1998;188:661-70.
26. McKinley MJ, Albiston AL, Allen AM, Mathai ML, May CN, McAllen RM, Oldfield BJ, Mendelsohn FA, Chai SY. The brain renin-angiotensin system: location and physiological roles. Int J Biochem Cell Biol 2003;35:901-18.
27. Muralidharan A, Wyse BD, Smith MT. Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioral, pharmacological, radiological, histological and immunohistochemical methods. Pharmacol Biochem Behav 2013;106:33-46.
28. Muralidharan A, Wyse BD, Smith MT. Analgesic efficacy and mode of action of a selective small molecule angiotensin II type 2 receptor antagonist in a rat model of prostate cancer-induced bone pain. Pain Med 2014;15:93-110.
29. Patil J, Schwab A, Nussberger J, Schaffner T, Saavedra JM, Imboden H. Intraneuronal angiotensinergic system in rat and human dorsal root ganglia. Regul Pept 2010;162:90-8.
30. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006;86:747-803.
31. Peart WS, Brown JJ. Effect of angiotensin (hypertensin or angiotonin) on urine flow and electrolyte excretion in hypertensive patients. Lancet 1961; 1:28-9.
32. Percie du Sert N, Rice AS. Improving the translation of analgesic drugs to the clinic: animal models of neuropathic pain. Br J Pharmacol 2014;171: 2951-63.
33. Plouffe B, Guimond MO, Beaudry H, Gallo-Payet N. Role of tyrosine kinase receptors in angiotensin II AT2 receptor signaling: involvement in neurite outgrowth and in p42/p44mapk activation in NG108-15 cells. Endocrinology 2006;147:4646-54.
34. Reinecke K, Lucius R, Reinecke A, Rickert U, Herdegen T, Unger T. Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: role of the AT2 receptor and the transcription factor NF-kappaB. FASEB J 2003;17:2094-6.
35. Rice AS, Dworkin RH, McCarthy TD, Anand P, Bountra C, McCloud PI, Hill J, Cutter G, Kitson G, Desem N, Raff M; EMA401-003 study group. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2014;383:1637-47.
36. Rolke R, Baron R, Maier C, Tolle TR, Treede RD, Beyer A, Binder A, Birbaumer N, Birklein F, Bötefür IC, Braune S, Flor H, Huge V, Klug R, Landwehrmeyer GB, Magerl W, Maihöfner C, Rolko C, Schaub C, Scherens A, Sprenger T, Valet M, Wasserka B. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values. PAIN 2006;123:231-43.
37. Rolke R, Magerl W, Campbell KA, Schalber C, Caspari S, Birklein F, Treede RD. Quantitative sensory testing: a comprehensive protocol for clinical trials. Eur J Pain 2006;10:77-88.
38. Smith MT, Lau T, Wallace VC, Wyse BD, Rice AS. Analgesic efficacy of small-molecule angiotensin II type 2 receptor antagonists in a rat model of antiretroviral toxic polyneuropathy. Behav Pharmacol 2014;25:137-46.
39. Smith MT, Muralidharan A. Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain. Expert Opin Ther Targets 2015;19:25-35.
40. Smith MT, Woodruff TM, Wyse BD, Muralidharan A, Walther T. A small molecule angiotensin II Type 2 receptor (AT2R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen activated protein kinase (MAPK) and p42/p44 MAPK activation in the dorsal root ganglia. Pain Med 2013;14:1557-68.
41. Smith MT, Wyse BD, Edwards SR. Small molecule Angiotensin II Type 2 receptor (AT2R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binDing and efficacy in rats. Pain Med 2013;14:692-705.
42. Stroth U, Blume A, Mielke K, Unger T. Angiotensin AT(2) receptor stimulates ERK1 and ERK2 in quiescent but inhibits ERK in NGFstimulated PC12W cells. Brain Res Mol Brain Res 2000;78:175-80.
43. Van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. PAIN 2014;155:654-62.
44. Verdonk K, Danser AH, van Esch JH. Angiotensin II type 2 receptor agonists: where should they be applied? Expert Opin Investig Drugs 2012;21:501-13.